{
    "name": "dulaglutide",
    "comment": "Rx",
    "other_names": [
        "Trulicity"
    ],
    "classes": [
        "Antidiabetics",
        "Glucagon-like Peptide-1 Agonists"
    ],
    "source": "https://reference.medscape.com/drug/trulicity-dulaglutide-999965",
    "pregnancy": {
        "common": [
            "Limited data in pregnant women are not sufficient to determine a drug associated risk for major birth defects and miscarriage",
            "There are clinical considerations regarding the risks of poorly controlled diabetes in pregnancy (eg, diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth, delivery complications)",
            "Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "Based on animal reproduction studies, there may be risks to the fetus from exposure to dulaglutide during pregnancy",
                    "In pregnant rats and rabbits administered dulaglutide during organogenesis, early embryonic deaths, fetal growth reductions, and fetal abnormalities occurred at systemic exposures at least 13 to 14-times human exposure at the maximum recommended human dose (MRHD) of 1.5 mg/week"
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "Poorly controlled diabetes in pregnancy increases maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications ",
                    "Poorly controlled diabetes increases fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity "
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of dulaglutide in human milk, the effects on breastfed infant, or effects on milk production",
            "Consider developmental and health benefits of breastfeeding along with motherâ€™s clinical need for therapy and any potential adverse effects on breastfed infant from therapy or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Risk of thyroid C-cell tumors",
                    "description": [
                        "Causes thyroid C-cell tumors in rodents; human risk could not be determined",
                        "Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN-2)",
                        "Counsel patients regarding potential risk of MTC with therapy and inform them of symptoms of thyroid tumors (e.g., mass in the neck, dysphagia, dyspnea, persistent hoarseness); routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients receiving therapy"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to drug or excipients",
                "Personal or family history of medullary thyroid carcinoma (MTC)",
                "Multiple endocrine neoplasia type 2 (MEN-2)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Systemic hypersensitivity reactions reported; anaphylaxis and angioedema reported with other GLP-1 receptor agonists; use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist; unknown whether such patients will be predisposed to anaphylaxis with drug; discontinue if such reactions occur",
                "Acute renal failure and worsening of chronic renal failure (some requiring hemodialysis) reported with treatment with glucagonlike peptide-1 (GLP-1) receptor agonists",
                "May be associated with GI adverse reactions, sometimes severe; counsel patients to take precautions to avoid fluid depletion; has not been studied in patients with severe GI disease, including severe gastroparesis",
                "Acute events of gallbladder disease such as cholelithiasis or cholecystitis reported in GLP-1 receptor agonist trials and postmarketing; serious events of acute cholecystitis reported; if cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated"
            ],
            "specific": [
                {
                    "type": "Diabetic retinopathy complications",
                    "description": [
                        "The REWIND CV outcomes trial (n = 9901; median follow up 5.4 yr) was conducted in patients with T2DM with established CV disease or multiple CV risk factors",
                        "Secondary composite endpoints showed diabetic retinopathy complications occurred in 1.9% of patients treated with dulaglutide compared with 1.5% treated with placebo ",
                        "Diabetic retinopathy complications were higher among patients with history of diabetic retinopathy at baseline (dulaglutide 8.5%, placebo 6.2%) compared with those without baseline history (dulaglutide 1%, placebo 1%)",
                        "Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy",
                        "Monitor for diabetic retinopathy progression in patients who have a history of diabetic retinopathy "
                    ]
                },
                {
                    "type": "Medullary thyroid carcinoma (MTC) ",
                    "description": [
                        "Nonclinical studies in rodents showed increased incidence of thyroid C-cell tumors (see Black Box Warnings and Contraindications)",
                        "Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value for early detection of MTC in patients treated with dulaglutide",
                        "Significantly elevated serum calcitonin may indicate MTC; patients with MTC usually have values >50 ng/L; evaluate patient further if serum calcitonin elevated",
                        "Evaluate patients with thyroid nodules noted on physical examination or neck imaging "
                    ]
                },
                {
                    "type": "Pancreatitis",
                    "description": [
                        "Acute pancreatitis reported (rare); after initiation of therapy",
                        "Observe for signs and symptoms of pancreatitis, including persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting",
                        "Discontinue if pancreatitis suspected and do not restart if confirmed; initiate appropriate management",
                        "Therapy has not been evaluated in patients with a prior history of pancreatitis; consider other antidiabetic therapies in patients with a history of pancreatitis"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Insulin secretagogues (eg, sulfonylureas) or insulin ",
                        "When initiating dulaglutide, consider reducing dosage of concomitantly administered insulin or insulin secretagogues to reduce risk of hypoglycemia ",
                        "Patients receiving drug in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia",
                        "The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin; inform patients using these concomitant medications of risk of hypoglycemia and educate them on signs and symptoms of hypoglycemia",
                        "Oral medications",
                        "Dulaglutide delays gastric emptying and, thus has potential to reduce rate of absorption of concomitantly administered oral medications ",
                        "Delay in gastric emptying is dose-dependent, but is attenuated with the recommended dose escalation to higher dulaglutide ",
                        "Delay is largest after the first dose and diminishes with subsequent doses ",
                        "In clinical pharmacology studies, dulaglutide 1.5 mg did not affect the absorption of the tested orally administered medications to a clinically relevant degree ",
                        "Limited experience with use of concomitant medications in clinical trials with 3-mg and 4.5-mg doses ",
                        "Monitor drug levels of oral medications with a narrow therapeutic index (eg, warfarin) when concomitantly administered "
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acarbose",
            "description": {
                "common": "dulaglutide, acarbose.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alogliptin",
            "description": {
                "common": "dulaglutide, alogliptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "canagliflozin",
            "description": {
                "common": "dulaglutide, canagliflozin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "dulaglutide, carbamazepine. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "dulaglutide, chlorpropamide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonidine",
            "description": {
                "common": "dulaglutide, clonidine. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "dulaglutide, cyclosporine. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dapagliflozin",
            "description": {
                "common": "dulaglutide, dapagliflozin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "dulaglutide, digoxin. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "disopyramide",
            "description": {
                "common": "dulaglutide, disopyramide. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "empagliflozin",
            "description": {
                "common": "dulaglutide, empagliflozin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethosuximide",
            "description": {
                "common": "dulaglutide, ethosuximide. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "dulaglutide, fosphenytoin. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glimepiride",
            "description": {
                "common": "dulaglutide, glimepiride.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "dulaglutide, glipizide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "dulaglutide, glyburide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "dulaglutide, insulin aspart.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart protamine/insulin aspart",
            "description": {
                "common": "dulaglutide, insulin aspart protamine/insulin aspart.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "dulaglutide, insulin degludec.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec/insulin aspart",
            "description": {
                "common": "dulaglutide, insulin degludec/insulin aspart.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "dulaglutide, insulin detemir.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "dulaglutide, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "dulaglutide, insulin glulisine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "dulaglutide, insulin inhaled.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin isophane human/insulin regular human",
            "description": {
                "common": "dulaglutide, insulin isophane human/insulin regular human.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "dulaglutide, insulin lispro.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro protamine/insulin lispro",
            "description": {
                "common": "dulaglutide, insulin lispro protamine/insulin lispro.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "dulaglutide, insulin NPH.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "dulaglutide, insulin regular human.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levothyroxine",
            "description": {
                "common": "dulaglutide, levothyroxine. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "linagliptin",
            "description": {
                "common": "dulaglutide, linagliptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lithium",
            "description": {
                "common": "dulaglutide, lithium. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lonapegsomatropin",
            "description": {
                "common": "lonapegsomatropin decreases effects of dulaglutide by Other (see comment). Use Caution/Monitor. \nComment: Closely monitor blood glucose when treated with antidiabetic agents. Lonapegsomatropin may decrease insulin sensitivity, particularly at higher doses. Patients with diabetes mellitus may require adjustment of their doses of insulin and/or other antihyperglycemic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metformin",
            "description": {
                "common": "dulaglutide, metformin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "miglitol",
            "description": {
                "common": "dulaglutide, miglitol.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "minoxidil",
            "description": {
                "common": "dulaglutide, minoxidil. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nateglinide",
            "description": {
                "common": "dulaglutide, nateglinide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "dulaglutide, phenobarbital. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "dulaglutide, phenytoin. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pioglitazone",
            "description": {
                "common": "dulaglutide, pioglitazone.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pramlintide",
            "description": {
                "common": "dulaglutide, pramlintide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prazosin",
            "description": {
                "common": "dulaglutide, prazosin. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "dulaglutide, primidone. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "procainamide",
            "description": {
                "common": "dulaglutide, procainamide. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinidine",
            "description": {
                "common": "dulaglutide, quinidine. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinine",
            "description": {
                "common": "dulaglutide, quinine. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "repaglinide",
            "description": {
                "common": "dulaglutide, repaglinide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rosiglitazone",
            "description": {
                "common": "dulaglutide, rosiglitazone.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saxagliptin",
            "description": {
                "common": "dulaglutide, saxagliptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sirolimus",
            "description": {
                "common": "dulaglutide, sirolimus. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sitagliptin",
            "description": {
                "common": "dulaglutide, sitagliptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "somapacitan",
            "description": {
                "common": "somapacitan decreases effects of dulaglutide by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone products may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating somapacitan. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "dulaglutide, tacrolimus. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "theophylline",
            "description": {
                "common": "dulaglutide, theophylline. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolazamide",
            "description": {
                "common": "dulaglutide, tolazamide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "dulaglutide, tolbutamide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valproic acid",
            "description": {
                "common": "dulaglutide, valproic acid. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "12.4-21.1"
        },
        {
            "name": "Increased amylase",
            "percent": "20"
        },
        {
            "name": "Increased lipase",
            "percent": "14"
        },
        {
            "name": "Diarrhea",
            "percent": "7-12.6"
        },
        {
            "name": "Abdominal pain",
            "percent": "6.5-9.4"
        },
        {
            "name": "Vomiting",
            "percent": "5.6-9.3"
        },
        {
            "name": "Decreased appetite",
            "percent": "4.9-8.6"
        },
        {
            "name": "Fatigue",
            "percent": "4.2-5.6"
        },
        {
            "name": "Dyspepsia",
            "percent": "2.3-5.8"
        },
        {
            "name": "Constipation",
            "percent": "3.7-3.9"
        },
        {
            "name": "Severe hypoglycemia with prandial insulin",
            "percent": "2.7-3.4"
        },
        {
            "name": "Flatulence",
            "percent": "1.4-3.4"
        },
        {
            "name": "Sinus tachycardia",
            "percent": "2.8-3"
        },
        {
            "name": "Abdominal distension",
            "percent": "2.3-2.9"
        },
        {
            "name": "Gastroesophageal reflux disease",
            "percent": "1.7-2"
        },
        {
            "name": "AV block",
            "percent": "0.9-1.7"
        },
        {
            "name": "Eructation",
            "percent": "0.6-1.6"
        },
        {
            "name": "Hypersensitivity",
            "percent": null
        },
        {
            "name": "sometimes severe",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "severe urticaria",
            "percent": null
        },
        {
            "name": "systemic rash",
            "percent": null
        },
        {
            "name": "facial edema",
            "percent": null
        },
        {
            "name": "lip swelling",
            "percent": null
        },
        {
            "name": "Injection",
            "percent": null
        },
        {
            "name": "site reactions",
            "percent": null
        },
        {
            "name": "Pancreatitis",
            "percent": null
        },
        {
            "name": "Cholelithaisis and cholecystitis",
            "percent": null
        },
        {
            "name": "Gastrointestinal",
            "percent": null
        },
        {
            "name": "Ileus",
            "percent": null
        },
        {
            "name": "Hepatobiliary",
            "percent": null
        },
        {
            "name": "Cholecystitis",
            "percent": null
        },
        {
            "name": "cholelithiasis requiring cholecystectomy",
            "percent": null
        },
        {
            "name": "cholestasis",
            "percent": null
        },
        {
            "name": "elevation of liver enzymes",
            "percent": null
        },
        {
            "name": "hepatitis",
            "percent": null
        },
        {
            "name": "Hypersensitivity",
            "percent": null
        },
        {
            "name": "Anaphylactic reactions",
            "percent": null
        },
        {
            "name": "angioedema",
            "percent": null
        },
        {
            "name": "Renal",
            "percent": null
        },
        {
            "name": "Acute renal failure or worsening of chronic renal failure",
            "percent": null
        },
        {
            "name": "sometimes requiring hemodialysis",
            "percent": null
        }
    ]
}